Works matching National Cancer Institute (NCI)

Results: 2464
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Synthetic Strategy toward Skeletal Diversity via Solid-Supported, Otherwise Unstable Reactive Intermediates ( We are especially grateful to John Tallarico and Max Narovlyansky at ICCB for the donation of synthesis resin. S.J.T. was supported by a postdoctoral fellowship (DRG-1735-02) of the Damon Runyon Cancer Research Foundation. A.M.T. was supported by a training grant managed by the Molecular, Cellular, and Chemical Biology Program. S.L.S. is an investigator at the Howard Hughes Medical Institute in the Department of Chemistry and Chemical Biology. We thank the National Institute for General Medical Sciences for their support of this research, the National Cancer Institute (NCI), Merck KGaA, Merck & Co., and the Keck Foundation for their support of ICCB, and the NCI for their support of the Initiative for Chemical Genetics. )

    Published in:
    Angewandte Chemie, 2004, v. 116, n. 13, p. 1713, doi. 10.1002/ange.200353466
    By:
    • Steven J. Taylor;
    • Alexander M. Taylor;
    • Stuart L. Schreiber
    Publication type:
    Article
    12

    Parallel Fragment Assembly Strategy Towards Multiple-Ether Mimicry of Anticancer Annonaceous Acetogenins ( This work was supported by the National Natural Science Foundation of China (grant no. 30271531), the Ministry of Science and Technology (MOST) of China (grant no. G2000077502), the Chinese Academy of Sciences (CAS; grant no. KGCX2-SW-209), and the Shanghai Municipal Committee of Science and Technology (grant no. 01QA14049). Dr. Terrence R. Burke, Jr. at the National Cancer Institute (NCI) is thanked for correcting the English text. )

    Published in:
    Angewandte Chemie, 2004, v. 116, n. 3, p. 333, doi. 10.1002/ange.200352681
    By:
    • Sheng Jiang;
    • Yan Li;
    • Xiao-Guang Chen;
    • Tai-Shan Hu;
    • Yu-Lin Wu;
    • Zhu-Jun Yao
    Publication type:
    Article
    13

    Expanding the Functional Group Compatibility of Small-Molecule Microarrays: Discovery of Novel Calmodulin Ligands () We are especially grateful to John Tallarico and Max Narovlyansky of the Harvard Institute of Chemistry and Cell Biology (ICCB) for donation of 2 b and synthesis resin, and to Jason Gatlin and Jennifer Raggio of the ICCB for their assistance with decoding. A.N.K. was supported by an Eli Lilly Predoctoral Fellowship. S.B.P. and D.B.-S. are Research Associates and S.L.S. is an Investigator at the Howard Hughes Medical Institute in the Department of Chemistry and Chemical Biology. We thank the National Institute for General Medical Sciences for support of this research, the National Cancer Institute (NCI), Merck KGaA, Merck & Co., and the Keck Foundation for support of the ICCB, and the NCI for support of the Initiative for Chemical Genetics (formerly known as the Molecular Target Laboratory).

    Published in:
    Angewandte Chemie, 2003, v. 115, n. 21, p. 2478, doi. 10.1002/ange.200351043
    By:
    • David Barnes-Seeman;
    • Seung Bum Park;
    • Angela N. Koehler;
    • Stuart L. Schreiber
    Publication type:
    Article
    14
    15
    16
    17

    National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.

    Published in:
    2019
    By:
    • George, Thomas J.;
    • Franke, Aaron J.;
    • Chakravarthy, A. Bapsi;
    • Das, Prajnan;
    • Dasari, Arvind;
    • El‐Rayes, Bassel F.;
    • Hong, Theodore S.;
    • Kinsella, Timothy J.;
    • Landry, Jerome C.;
    • Lee, James J.;
    • Monjazeb, Arta M.;
    • Jacobs, Samuel A.;
    • Raben, David;
    • Rahma, Osama E.;
    • Williams, Terence M.;
    • Wu, Christina;
    • Coleman, C. Norman;
    • Vikram, Bhadrasain;
    • Ahmed, Mansoor M.;
    • El-Rayes, Bassel F
    Publication type:
    journal article
    18
    19
    20
    21
    22
    23

    Synthetic Strategy toward Skeletal Diversity via Solid-Supported, Otherwise Unstable Reactive Intermediates ( We are especially grateful to John Tallarico and Max Narovlyansky at ICCB for the donation of synthesis resin. S.J.T. was supported by a postdoctoral fellowship (DRG-1735-02) of the Damon Runyon Cancer Research Foundation. A.M.T. was supported by a training grant managed by the Molecular, Cellular, and Chemical Biology Program. S.L.S. is an investigator at the Howard Hughes Medical Institute in the Department of Chemistry and Chemical Biology. We thank the National Institute for General Medical Sciences for their support of this research, the National Cancer Institute (NCI), Merck KGaA, Merck & Co., and the Keck Foundation for their support of ICCB, and the NCI for their support of the Initiative for Chemical Genetics. )

    Published in:
    Angewandte Chemie International Edition, 2004, v. 43, n. 13, p. 1681, doi. 10.1002/anie.200353466
    By:
    • Steven J. Taylor;
    • Alexander M. Taylor;
    • Stuart L. Schreiber
    Publication type:
    Article
    24

    Parallel Fragment Assembly Strategy Towards Multiple-Ether Mimicry of Anticancer Annonaceous Acetogenins ( This work was supported by the National Natural Science Foundation of China (grant no. 30271531), the Ministry of Science and Technology (MOST) of China (grant no. G2000077502), the Chinese Academy of Sciences (CAS; grant no. KGCX2-SW-209), and the Shanghai Municipal Committee of Science and Technology (grant no. 01QA14049). Dr. Terrence R. Burke, Jr. at the National Cancer Institute (NCI) is thanked for correcting the English text. )

    Published in:
    Angewandte Chemie International Edition, 2004, v. 43, n. 3, p. 329, doi. 10.1002/anie.200352681
    By:
    • Sheng Jiang;
    • Yan Li;
    • Xiao-Guang Chen;
    • Tai-Shan Hu;
    • Yu-Lin Wu;
    • Zhu-Jun Yao
    Publication type:
    Article
    25

    Expanding the Functional Group Compatibility of Small-Molecule Microarrays: Discovery of Novel Calmodulin Ligands ( We are especially grateful to John Tallarico and Max Narovlyansky of the Harvard Institute of Chemistry and Cell Biology (ICCB) for donation of 2 b and synthesis resin, and to Jason Gatlin and Jennifer Raggio of the ICCB for their assistance with decoding. A.N.K. was supported by an Eli Lilly Predoctoral Fellowship. S.B.P. and D.B.-S. are Research Associates and S.L.S. is an Investigator at the Howard Hughes Medical Institute in the Department of Chemistry and Chemical Biology. We thank the National Institute for General Medical Sciences for support of this research, the National Cancer Institute (NCI), Merck KGaA, Merck & Co., and the Keck Foundation for support of the ICCB, and the NCI for support of the Initiative for Chemical Genetics (formerly known as the Molecular Target Laborato)

    Published in:
    Angewandte Chemie International Edition, 2003, v. 42, n. 21, p. 2376, doi. 10.1002/anie.200351043
    By:
    • David Barnes-Seeman;
    • Seung Bum Park;
    • Angela N. Koehler;
    • Stuart L. Schreiber
    Publication type:
    Article
    26

    Participation of Asian‐American women in cancer chemoprevention researchPresented at Asian American Network for Cancer Awareness, Research, and Training (AANCART): Fifth Asian American Cancer Control Academy, Sacramento, California, October 22–23, 2004.Supported by an Administrative Supplement to the Cancer Research Network CRN; with funding from the National Cancer Institute [NCI] grant U19/CA 79689), consists of the research programs, enrollee populations, and databases from 10 health maintenance organizations (HMOs) that are members of the Network.: Physician perspectives

    Published in:
    Cancer (0008543X), 2005, v. 104, p. 3006
    By:
    • Tung T. Nguyen;
    • Carol P. Somkin;
    • Yifei Ma
    Publication type:
    Article
    27

    Age and comorbidity impact surgical therapy in older bladder carcinoma patientsSee related editorials on pages 1559–62 and pages 1563–6, this issue.This work is a collaboration of the National Institute on Aging (NIA) and National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Study on Comorbidity and Cancer in the Elderly.: A population‐based study

    Published in:
    Cancer (0008543X), 2005, v. 104, n. 8, p. 1638
    By:
    • George R. Prout;
    • Margaret N. Wesley;
    • Rosemary Yancik;
    • Lynn A. G. Ries;
    • Richard J. Havlik;
    • Brenda K. Edwards
    Publication type:
    Article
    28

    Childbearing and survival after breast carcinoma in young women<FN ID="fn2">Cancer data were supported by the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center (funded by Contract No. N01-CN-05230 from the Surveillance, Epidemiology, and End Results [SEER] Program of the National Cancer Institute [NCI] with additional funding from the Fred Hutchinson Cancer Research Center) in the Seattle region. In Los Angeles, cancer incidence data were collected under a subcontract with the Public Health Institute. The subcontract is supported by the California Department of Health Services within the statewide cancer reporting program, mandated by Health and Safety Code Section 103875 and 103885. The University of Southern California Los Angeles County Cancer Surveillance Program is funded by Contract No. NO1-PC-67010 from the SEER Program of the NCI. Cancer incidence data for Detroit were collected by the Metropolitan Detroit Cancer Surveillance System of Wayne State University/Karmanos Cancer Institute and funded by Contract No. NO1-CN-65064 from the SEER Program of the NCI. Vital statistics data were provided by the Washington State Department of Health Center for Health Statistics; the California Department of Health Services, Center for Health Statistics, Vital Statistics Section; and the Vital and Health Record Section, Department of Community Health, Community Public Health Agency of the State of Michigan</FN>

    Published in:
    Cancer (0008543X), 2003, v. 98, n. 6, p. 1131, doi. 10.1002/cncr.11634
    By:
    • Beth A. Mueller;
    • Michael S. Simon;
    • Dennis Deapen
    Publication type:
    Article
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45

    Cancer biomarkers

    Published in:
    Molecular Oncology, 2012, v. 6, n. 2, p. 140, doi. 10.1016/j.molonc.2012.01.010
    By:
    • Henry, N. Lynn;
    • Hayes, Daniel F.
    Publication type:
    Article
    46
    47
    48
    49

    Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1–associated atypical neurofibromas.

    Published in:
    Neuro-Oncology, 2019, v. 21, n. 8, p. 981, doi. 10.1093/neuonc/noz028
    By:
    • Pemov, Alexander;
    • Hansen, Nancy F;
    • Sindiri, Sivasish;
    • Patidar, Rajesh;
    • Higham, Christine S;
    • Dombi, Eva;
    • Miettinen, Markku M;
    • Fetsch, Patricia;
    • Brems, Hilde;
    • Chandrasekharappa, Settara C;
    • Jones, Kristine;
    • Zhu, Bin;
    • Wei, Jun S;
    • Program, National Intramural Sequencing Center (NISC) Comparative Sequencing;
    • Laboratory, National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) Cancer Genomics Research;
    • Mullikin, James C;
    • Wallace, Margaret R;
    • Khan, Javed;
    • Legius, Eric;
    • Widemann, Brigitte C
    Publication type:
    Article
    50